Its sales rose at a double-digit rate; net profit growth was more modest. There's another developmen

Vertex's Q2 earnings miss estimates, but revenues beat. It lifts its 2026 sales outlook, and sees gr

Vertex raises its 2026 revenue outlook as CF growth, newer products and a near-term renal launch str

Vertex Pharmaceuticals Incorporated (VRTX) Q2 2026 Earnings Call Transcript

Vertex Pharmaceuticals NASDAQ: VRTX reported second-quarter 2026 revenue growth of 12% year over yea

Although the revenue and EPS for Vertex (VRTX) give a sense of how its business performed in the qua

Vertex Pharmaceuticals (VRTX) came out with quarterly earnings of $4.73 per share, missing the Zacks

Vertex stock dipped late Monday on a mixed second-quarter report. But the biotech giant raised its s

Vertex Pharmaceuticals on Monday raised the upper end of its annual revenue forecast, banking on rob

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolida

U.S. stock futures up, focus on earnings from Tyson Foods, Marriott, Universal Logistics, Williams C

CNN Money Fear & Greed index improved while remaining in 'Fear' zone on Friday. Amazon u

Evaluate the expected performance of Vertex (VRTX) for the quarter ended June 2026, looking beyond t

Amundi lifted its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) by 12.9% during the

Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $490.39, moving +2.38% from the

Vertex (VRTX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exp

Vertex (VRTX) doesn't possess the right combination of the two key ingredients for a likely earnings

In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $472.57, marking a -1.96% mov

ABN Amro Investment Solutions boosted its position in Vertex Pharmaceuticals Incorporated (NASDAQ: V

Andra AP fonden cut its holdings in shares of Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) by

Amova Asset Management Americas Inc. lowered its stake in Vertex Pharmaceuticals Incorporated (NASDA

Seven small-cap stocks have surged as much as 123% in early July on buyouts, FDA developments, refin

In the closing of the recent trading day, Vertex Pharmaceuticals (VRTX) stood at $480.5, denoting a

Vertex Pharmaceuticals (NASDAQ:VRTX) has outperformed the market over the past 5 years by 7.55% on a

UBS analyst Michael Yee maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Buy and raises the

Truist Securities analyst Danielle Brill maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Bu

The Halftime Report Final Trades featured stock picks from Bryn Talkington, Jim Lebenthal, Liz Young

Vertex to acquire Crinetics for $10 billion, adding approved acromegaly drug Palsonify and late-stag

Crinetics Pharmaceuticals Inc (NASDAQ: CRNX) rose in pre-market trading after being acquired by Vert

Crinetics Pharmaceuticals shares are trading higher in Monday's after-hours session after the co

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) and Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX),

U.S. stocks sank Monday as an Iranian drone attack on a UAE petroleum site sent Brent above $114, go

U.S. stocks rose broadly on Tuesday as crude oil plunges over 10% on Trump's Iran end-of-war sig

CRISPR Therapeutics fell Tuesday after unveiling a $350 million convertible notes offering, overshad

Dow Jones index up 200 points on Tuesday, NIO Inc. gained following better-than-expected financial r

After Thursday's broad-based tech selloff, Wall Street staged a rebound as a softer-than-expecte

CRISPR Therapeutics highlights progress in clinical trials & uptake of Casgevy gene therapy. Pip

Investors are anticipating reports from Robinhood, Pinterest, Rivian and more. Here's a look at

Risk appetite cooled on Tuesday as investors interpreted the latest batch of corporate earnings as s

Wall Street opened the week on a mixed note on Monday.

This whale alert can help traders discover the next big trading opportunities. Whales are entities w

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analys

Forecasts in biotech market indicate that by 2030, gene therapy will become more accessible, potenti

Large-cap laggards slid on weak results/guidance, cuts and capital moves—led by The Trade Desk, Fort